Advertisement

Topics

Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

18:25 EST 9 Nov 2017 | BioPortfolio Report Blog

Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 Pipeline Review, H2 2017


Summary


According to the recently published report 'Glucose Dependent Insulinotropic Receptor Pipeline Review, H2 2017'; Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.


Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 G proteincoupled receptor 119 also known as GPR119 is a G proteincoupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes.


The report 'Glucose Dependent Insulinotropic Receptor Pipeline Review, H2 2017' outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Respiratory and Undisclosed which include indications Type 2 Diabetes, Obesity, Chronic Obstructive Pulmonary Disease COPD, Dyslipidemia and Unspecified.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119

The report reviews Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 targeted therapeutics and enlists all their major and minor projects

The report assesses Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Glucose Dependent Insulinotropic Receptor G Protein Coupled Receptor 119 or GPR119 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...